The latest from BioStock
» Cyxone's CEO: "Significantly lower risk in project development"
» Mentice sets new sales record
» Abliva's CEO: "One step closer to a market-approved drug"
» Cyxone updates development plan
» BioInvent and MSD to evaluate new treatment for metastatic melanoma
The latest news
Partner Eisai shows preliminary sales figures for leqembi of 6,3 billion yen in Q2 2024, giving BioArctic a royalty of 43 MSEK. Read more.
Ultimovacs announces poster presentation of update of the phase II study NIPU at upcoming ESMO Congress 2024. Read more.
Immunovia files patent application in the US to protect next-generation test. Read more.
Swedencare has completed the acquisition of WithVant and carries out an issue of shares to the sellers. Read more.
Calliditas Therapeutics will participate in the leadership conference Women in Nephrology (WIN). Read more.
Flerie provides information about the net asset value. Read more.
Qlife Holding announces recalculation of warrants. Read more.
Reports
This morning's price development
Index: OMXS30 -1,79% Healthcare -0,85%
| Winner | Förlorare |
| Arcede Pharma +77,4% | Bio-Works -19,5% |
| Odinwell +16,1% | Immunovia -15,6% |
| SoftOx Solutions +15,5% | Ecti Research -14,1% |
| Polymer Factory +13,8% | Acarix -10,3% |
| Sperm count +7,2% | Carbiotix -10,2% |